Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial.
Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica: Multicenter Study of Treatment Efficacy.
Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity.
Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
Mycophenolate Mofetil as a Monotherapy in Multiple Sclerosis: a multicentre retrospective study on 361 patients
Breast-feeding, postpartum and prepregnancy disease activity in multiple sclerosis.
RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation.
Immunomodulatory agents and risk of postpartum multiple sclerosis relapses.
Prevention and Mitigation of Experimental Autoimmune Encephalomyelitis by Murine β-Defensins via Induction of Regulatory T Cells.
Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients.
Low testosterone is associated with disability in men with multiple sclerosis.
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.
Combination of IFN beta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis.
Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells.
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
Mycophenolate mofetil improves neurological function and alters blood T-lymphocyte subsets in rats with experimental autoimmune encephalomyelitis.
USPTO list of patent term extensions
Epitope spreading as an early pathogenic event in pediatric multiple sclerosis.
High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS): A 3-Year Interim Report.
Glatiramer promotes oligodendroglial cell maturation in a cuprizone-induced demyelination model.
TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
Defining the clinical course of multiple sclerosis: The 2013 revisions.
A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).
Development of oral immunomodulatory agents in the management of multiple sclerosis.

Pages